Patent-Eligible Subject Matter in the U.S. (the road ahead)
|Date:||10 February 2015|
Last month, our Melbourne office hosted BioMelbourne’s sold-out BioBriefing: “Hot or Not: Trends for 2015.” A panel of five discussed how innovation will continue to drive the life sciences sector in 2015, and what lies ahead for the biotech and medtech industry in Victoria.
Panel member and FB Rice Overseas Qualified Attorney, Dr. Ken Seidenman, discussed Patent-Eligible Subject Matter in the U.S. and how to best navigate the road ahead based on recent case law and the USPTO’s new interim guidelines on patent eligibility of “nature-based product" claims.
|Tags:||USPTO, Patent-eligible subject matter, BioBriefing, BioMelbourne, Victoria, biotech, medtech|